Research programme: glycogen synthase kinase-3 inhibitors - Eli Lilly

Drug Profile

Research programme: glycogen synthase kinase-3 inhibitors - Eli Lilly

Alternative Names: 603281-31-8; LY-GSK-3i

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Azepines; Indoles; Pyrroles; Small molecules
  • Mechanism of Action Apoprotein stimulants; Cell cycle modulators; Glycogen synthase kinase 3 inhibitors; Osteogenesis stimulants; Signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer; Muscular atrophy; Type 2 diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer(Combination therapy) in USA
  • 20 Apr 2010 Pharmacodynamics data from preclinical trials in Cancer presented at the 101st Annual Meeting of the American Association for Cancer Research
  • 14 Dec 2009 Pharmacodynamics data from a preclinical trial in Cancer presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top